Repligen Co. (NASDAQ:RGEN) Shares Sold by Zevenbergen Capital Investments LLC

Zevenbergen Capital Investments LLC lessened its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 12.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 112,747 shares of the biotechnology company's stock after selling 16,223 shares during the quarter. Zevenbergen Capital Investments LLC owned approximately 0.20% of Repligen worth $16,229,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of RGEN. UMB Bank n.a. lifted its position in shares of Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 110 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Repligen during the 4th quarter worth approximately $216,000. Worldquant Millennium Advisors LLC lifted its holdings in Repligen by 11.9% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 50,276 shares of the biotechnology company's stock worth $7,482,000 after buying an additional 5,337 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Repligen by 1.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 363,379 shares of the biotechnology company's stock valued at $54,078,000 after buying an additional 5,478 shares during the period. Finally, Van ECK Associates Corp grew its stake in shares of Repligen by 7.8% in the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after acquiring an additional 3,066 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity

In other Repligen news, Director Margaret Pax acquired 250 shares of the stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the transaction, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Repligen in a report on Friday, February 21st. StockNews.com cut Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. TD Cowen initiated coverage on shares of Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. Finally, Evercore ISI assumed coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, Repligen presently has an average rating of "Hold" and a consensus price target of $178.64.

Remove Ads

Repligen Stock Performance

Shares of RGEN stock opened at $140.02 on Monday. The stock's 50-day moving average is $156.18 and its two-hundred day moving average is $148.40. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $198.00. The firm has a market cap of $7.86 billion, a price-to-earnings ratio of -274.55, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.